Tolazamide
From Wikipedia, the free encyclopedia
 |
|
|
Tolazamide
|
|
| Systematic (IUPAC) name | |
| 3-azepan-1-yl-1-(4-methylphenyl)sulfonyl-urea | |
| Identifiers | |
| CAS number | |
| ATC code | A10 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C14H21N3O3S |
| Mol. mass | 311.401 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | 7 hours |
| Excretion | Renal (85%) and fecal (7%) |
| Therapeutic considerations | |
| Licence data |
|
| Pregnancy cat. | |
| Legal status | |
| Routes | Oral |
Tolazamide is an oral blood glucose lowering drug used for people with Type 2 diabetes. It is part of the sulfonamide family (ATC A10BB).
[edit] External links
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
